🎈 Up Big Today: Find today's biggest gainers with our free screenerTry Stock Screener

Ptc Therapeutics exec VP sells shares worth $5 million

Published 04/12/2024, 22:24
PTCT
-

In a recent series of transactions, Mark Elliott Boulding, Executive Vice President and Chief Legal Officer of PTC Therapeutics, Inc. (NASDAQ:PTCT), a $3.84 billion market cap company whose stock has surged nearly 81% year-to-date, executed significant sales of the company's stock. According to InvestingPro analysis, the stock is currently trading above its Fair Value. On December 2 and 3, Boulding sold a total of 95,003 shares, with transaction prices ranging from $52.17 to $54.14 per share, near the stock's 52-week high of $54.16. These sales amounted to approximately $5,022,334. For comprehensive insider trading analysis and 12+ additional key insights about PTCT, consider accessing the full research report on InvestingPro.

The transactions were conducted under a pre-established Rule 10b5-1 trading plan, adopted by Boulding on October 31, 2023. This type of plan allows company insiders to set up a predetermined schedule for selling stocks, which can help avoid potential accusations of insider trading.

In addition to the sales, Boulding also exercised stock options, acquiring shares at prices between $33.02 and $51.00, totaling $4,705,970 in value. Following these transactions, Boulding holds 92,389 shares of PTC (NASDAQ:PTC) Therapeutics.

In other recent news, PTC Therapeutics has seen significant developments, with a focus on its collaboration with Novartis (LON:0QLR) (SIX:NOVN). The deal, which includes a $1.0 billion upfront payment and potential for up to $1.9 billion in future milestone payments, centers on the drug candidate PTC518, currently under evaluation for the treatment of Huntington's disease. Analysts from Citi, Goldman Sachs (NYSE:GS), and Baird have adjusted their price targets for PTC Therapeutics, reflecting the company's strategic partnership and promising pipeline. While Citi and Goldman Sachs maintain a Sell rating, Baird continues to hold an Outperform rating on the stock.

PTC Therapeutics reported robust third-quarter earnings, with total revenue reaching $197 million, primarily driven by the Duchenne muscular dystrophy franchise. The company has also increased its 2024 revenue outlook to between $750 million and $800 million. With the support of Novartis, PTC Therapeutics plans to design a Phase 3 efficacy trial for PTC518, and is preparing for global product launches, including those of sepiapterin and vatiquinone, with potential revenue exceeding $1 billion in the U.S. alone.

Despite these positive developments, Goldman Sachs highlighted ongoing risks for PTC Therapeutics, including the durability of Translarna sales in the EU and forthcoming regulatory decisions in the US for Translarna and vatiquinone. These recent developments provide investors with a snapshot of PTC Therapeutics' current financial position and strategic partnerships.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.